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According to American Heart Association/American College of Cardiology Practice Guide-
lines, electrolyte abnormalities, including abnormal serum potassium concentrations, are
considered a correctable cause of a life-threatening ventricular arrhythmia. Ventricular
defibrillator therapy in this situation is a class III indication, and thought to be ineffective and
perhaps harmful, although there are minimal data to support this recommendation. The
steady-state serum potassium concentration frequently changes during a cardiac arrest.
Additionally, the vast majority of cardiac arrest patients have structural heart disease and are
commonly treated with a variety of medications that can alter the serum potassium
concentration. In the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial,
patients with a correctable cause of an electrolyte imbalance were excluded from study
participation but were followed in the AVID registry. Similar outcomes were observed among
patients in the AVID registry and the main trial. Spironolactone therapy in patients with
congestive heart failure decreases all-cause mortality and sudden and nonsudden cardiac
death. In a preliminary study of 169 patients with an episode of a sustained ventricular
arrhythmia treated with an implantable defibrillator, freedom from appropriate defibrillator
therapy was 18% after five years. The probability of appropriate defibrillator therapy was
independent of the initial serum potassium concentration. For these reasons, our current
clinical practice is to use an implantable defibrillator to treat an initial episode of sustained
ventricular tachycardia or ventricular fibrillation that occurs in a patient with structural heart
disease and an abnormal serum potassium concentration. (J Am Coll Cardiol 2001;38:
1224–5) © 2001 by the American College of Cardiology
According to American Heart Association/American Col-
lege of Cardiology (AHA/ACC) Practice Guidelines, elec-
trolyte abnormalities, including abnormal serum potassium
concentrations, are considered a correctable cause of a
life-threatening ventricular arrhythmia (1). Ventricular de-
fibrillator therapy in this situation is a class III indication,
thought to be ineffective and perhaps harmful (1), although
there are minimal data to support this recommendation. In
fact, interpretation of a serum potassium concentration in
the setting of a cardiac arrest can be difficult because of the
well-recognized association between acute stress and hypo-
kalemia. Moreover, the vast majority of cardiac arrest
patients have structural heart disease. A variety of medica-
tions that can alter the serum potassium concentration,
including angiotensin-converting enzyme inhibitors and
diuretics, are commonly used to treat patients who have
structural heart disease, making strict control of serum
potassium concentration difficult. Therefore, we propose
that there is a substantial risk of a recurrent sustained
ventricular arrhythmia in patients with underlying structural
heart disease and an abnormal serum potassium concentra-
tion measured at the time of an initial life-threatening
arrhythmic event, and that treatment of these patients with
an implantable defibrillator is reasonable and appropriate.
Limited clinical data address the relationship between the
serum potassium concentration and the risk of recurrent
ventricular arrhythmias. After an initial episode of ventric-
ular tachycardia or ventricular fibrillation that occurred in
the setting of an abnormal serum potassium concentration,
the risk of recurrent ventricular tachycardia or ventricular
fibrillation has been addressed in one previously published
study of 10 patients (2). In this study, torsades de pointes
was likely responsible for the recurrent cardiac arrest in six
of the patients (2). The Antiarrhythmics Versus Implant-
able Defibrillators (AVID) trial classified “electrolyte imbal-
ances” as correctable causes of ventricular tachycardia or
ventricular fibrillation, and excluded these patients (3).
However, all excluded patients were followed in the AVID
registry (4). Similar outcomes were observed among patients
in the registry and the main trial. Finally, spironolactone
therapy has been shown to decrease all-cause mortality and
sudden and nonsudden cardiac death in patients with
congestive heart failure (5). The mechanism responsible for
this effect is not known. However, maintenance of a normal
serum potassium concentration may be responsible.
We recently completed a preliminary study designed to
assess the risk of a recurrent sustained ventricular arrhyth-
mia in patients in whom an abnormal serum potassium
concentration was measured at the time of an initial episode
of a sustained ventricular arrhythmia (6). This study in-
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cluded 169 consecutive patients with structural heart dis-
ease, sustained ventricular tachycardia, ventricular fibrilla-
tion or syncope and inducible sustained ventricular
tachycardia in whom a serum potassium concentration was
measured on the day of the initial arrhythmia, and who
underwent defibrillator implantation. The mean left ven-
tricular ejection fraction was 0.32 6 0.15, all of the patients
had structural heart disease and (8%) were treated with a
class I or III antiarrhythmic agent at the time of the initial
ventricular arrhythmia. An abnormal serum potassium con-
centration was present in 31% of patients and a serum
potassium concentration ,3.0 mEq/l or .6.0 mEq/l was
present in 11 patients. The ability to store intracardiac
electrograms was present in approximately half of the
implanted defibrillators. During a mean follow-up period of
3.1 6 2.8 years, appropriate defibrillator therapy occurred in
102 of 169 (60%) patients. After five years, freedom from
appropriate defibrillator therapy was 18% (Fig. 1). The
probability of appropriate defibrillator therapy during
follow-up of the 11 patients with a serum potassium
concentration ,3.0 mEq/l or .6.0 mEq/l was similar.
However, while not significantly different, there was a trend
that suggested a reduced rate of appropriate defibrillator
therapies among patients with a serum potassium concen-
tration that was ,3.5 mEq/l, as compared to between
3.5 mEq/l and 5 mEq/l, and .5 mEq/l on the day of the
initial sustained ventricular arrhythmia (Fig. 1).
According to the AHA/ACC Practice Guidelines, “there
is evidence and/or general agreement that [implantation of
a defibrillator] is not useful/effective and in some cases may
be harmful” when “ventricular tachyarrhythmias due to a
transient or reversible disorder (e.g., AMI, electrolyte im-
balance, drugs, trauma)” are identified (1). But “electrolyte
imbalance” must be taken in the clinical context. A cardiac
arrest due to ventricular tachycardia or ventricular fibrilla-
tion in a 22-year-old patient who does not have structural
heart disease and who has severe diarrhea and a serum
potassium concentration of 1.7 mEq/l, is a very different
situation than a cardiac arrest in a patient with a severe
cardiomyopathy and a serum potassium concentration of
2.4 mEq/l. From a therapeutic perspective, it is appropriate
to differentiate between these two patients, even though
both have an electrolyte imbalance. Based on our recent
data, we believe that hyokalemia may be associated with a
reduced risk of recurrent ventricular tachycardia or ventric-
ular fibrillation in patients with structural heart disease,
although the risk is still substantial. Therefore, our current
practice is generally to treat an initial episode of sustained
ventricular tachycardia or ventricular fibrillation in patients
with structural heart disease and an abnormal serum potas-
sium concentration with an implantable defibrillator.
Clearly, additional research is needed to address this issue.
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Figure 1. The probability of defibrillator therapy-free survival based on the
serum potassium concentration ([k1]) at the time of the initial episode of
ventricular tachycardia or ventricular fibrillation is shown. (Units for serum
potassium concentration are mEq/l). ICD 5 implantable cardioverter
defibrillator.
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